MILWAUKEE, Aug. 5, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Zymergen (NASDAQ: ZY). The investigation results from inaccurate statements Zymergen may have made regarding its business operations and prospects.
The investigation focuses on whether Zymergen has properly disclosed technical issues in implementing Hyaline that will impact the Zymergen's delivery timeline and revenue projections. As a result, Zymergen will have no product revenue in 2021 and immaterial product revenue in 2022. Josh Hoffman has resigned as CEO and as a member of the Board.